This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of Tor Kinase Inhibitor in Advanced Tumors

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: August 6, 2008
Last updated: July 10, 2012
Last verified: July 2012
The purpose of the study is to assess the safety, tolerability and pharmacokinetics of AZD8055 and determine the maximum tolerated dose to take into phase II trials.

Condition Intervention Phase
Solid Tumors Drug: AZD8055 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II, Open-Label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Tor Kinase Inhibitor AZD8055 Administered Orally to Patients With Advanced Solid Tumours.

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Safety and tolerability of AZD8055 [ Time Frame: Assessed at all visits ]

Secondary Outcome Measures:
  • To identify early signals of anti-tumour activity [ Time Frame: Visits 1, 5, and 9 and 11 ]
  • To identify early signals of anti-tumor activity [ Time Frame: Visits 1, 5, 9 and 13 ]

Enrollment: 64
Study Start Date: July 2008
Study Completion Date: November 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
The study will start with AZD8055 formulated in a liquid solution prior to the tablet formulation becoming available. The tablet formulation will be introduced in Part A at the beginning of a new cohort at an appropriate dose, no higher than the dose of the liquid formulation in the last completed evaluated cohort. Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
Drug: AZD8055
Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological or cytological confirmation of an advanced solid malignant tumour (or lymphoma Part A only)
  • Cancer which is refractory to standard therapies or for which no standard therapy exists, patients with measurable or non-measurable disease (according to RECIST criteria) can be recruited to Part A
  • Evidence of post-menopausal status or negative urine/serum pregnancy test for pre-menopausal female patients

Exclusion Criteria:

  • Patients with severe laboratory abnormalities for haematology, liver or renal function. Also treatment with any haemopoietic growth factors are not allowed within two weeks from first dose of study drug.
  • Patients with abnormal fasting glucose, have type I or II Diabetes or have uncontrolled blood fats and cholesterol
  • Patients with a history of neurological disease, peripheral or central neuropathy, brain metastases or family history of myopathy are excluded
  • Patients with severe cardiac condition of ischemia, impaired ventricular function and arrhythmias, evidence of severe or uncontrolled systemic or current unstable or uncompensated respiratory or cardiac conditions
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00731263

United States, New York
Research Site
New York, New York, United States, 10065
United States, Texas
Research Site
Houston, Texas, United States
Research Site
Clichy, France
United Kingdom
Research Site
Sutton, Surrey, United Kingdom
Sponsors and Collaborators
Principal Investigator: Prof Stan Kaye Royal Marsden Hospital, Sutton, Surrey, England, SM2 5PT
Principal Investigator: Dr Carol Aghajanian Memorial Sloan-Kettering Cancer Centre, 1275 York Avenue, New York, NY 10065, USA
Principal Investigator: Dr Aung Naing MD Anderson Cancer Centre, 1515 Holcombe Blvd, Houston, Texas, USA
Principal Investigator: Professor Eric Raymond Hôpital Beaujon, 100, Boulevard du Général Leclerc, 92118 Clichy Cedex, France
  More Information

Responsible Party: AstraZeneca Identifier: NCT00731263     History of Changes
Other Study ID Numbers: D1600C00001
Study First Received: August 6, 2008
Last Updated: July 10, 2012

Keywords provided by AstraZeneca:
Advance solid tumours
Dose Escalation
Preliminary efficacy
Tor kinase inhibitor
Oral administration processed this record on September 19, 2017